Provider: Wright Reports
Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Actelion Ltd Reaffirms FY 2012 Guidance; Reaffirmed FY 2013 EPS Guidance; Comments On FY 2014, 2015 EPS Guidance
Actelion Ltd reaffirmed fiscal 2012 guidance and expected product sales to be low-single digit decline and mid-single digit core earnings growth. The Company also reaffirmed fiscal 2013 guidance with core earnings flat compared to the higher fiscal 2012 base, returning to single digit growth in fiscal 2014 and double digit growth in fiscal 2015.
Latest Developments for Actelion Ltd
- Actelion Ltd Receives US FDA Approval Of Opsumit For The Treatment Of Pulmonary Arterial Hypertension
- Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics
- Actelion Ltd Raises FY 2013 EPS Guidance; Updates FY 2014 EPS Guidance; Lowers FY 2015 EPS Guidance-DJ
- Actelion Ltd Issues FY 2013 EPS Guidance Above Analysts' Estimates; Comments On FY 2014 And FY 2015 EPS Guidance-Conference Call
Latest Key Developments in Biotechnology
- Dyax Corp receives orphan drug designation from the U.S. FDA for DX-2930 in hereditary angioedema
- Genmab to be included in OMXC20CAP and OMXC20 indexes-Reuters
- Immunicum AB announces positive results for cancer vaccine INTUVAX in treatment of kidney cancer
- Zealand Pharma says data presented by Sanofi support flexibility in timing of administration for Lyxumia
- Share this
- Digg this